PubMedNature biotechnology2026-11-11
Biotech news from around the world.
PMID 43009589
Read full article →Drug Database
IN
insulin
✓ ApprovedMJ Biotech · INSR · Recombinant Proteins
What is insulin?
insulin is a recombinant proteins developed by MJ Biotech. It is approved for therapeutic indications via injectable (others).
Drug Profile
| Company | MJ Biotech |
| Drug Class | Recombinant Proteins |
| Molecular Target | INSR |
| Route | Injectable (Others) |
| Status | Approved |
Sources: ClinicalTrials.gov, MJ Biotech
Mechanism of Action
Molecular Targets
insulin acts on 1 molecular target:
| INSR | insulin receptor (CD220, HHF5) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
insulin is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Investigations | Glucose tolerance test abnormal | ✓ Approved |
Related Research Articles
PubMedNature biotechnology2026-11-11
China plans ban on biotech exports.
PMID 43009587
Read full article →PubMedNature biotechnology2026-11-11
Three questions with climate biotech startup founders.
Francisco Michael M
PMID 43009577
Read full article →PubMedDiabetic medicine : a journal of the British Diabetic Association2026-11-11
The road ahead for stem cell therapies in type 1 diabetes.
Gasa Rosa R, Sancho Rocio R, Spagnoli Francesca M FM
Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic β-cells. Although exogenous insulin remains the standard treatment, it does not restore physiological glucose regulation. Differentiation of human pluripotent stem cells into β-cells offers a scalable alternative to cadaveric islet transplantation and has progressed rapidly over the past decade, resulting in nine clinical trials at various stages of completion. Despite this progress, durable graft function remains constrained by two major challenges: the absence of key islet microenvironment components, such as vasculature, extracellular matrix and supporting cell types and continued vulnerability to autoimmune and alloimmune rejection. This review considers emerging technological approaches to overcome these barriers. Bioengineered niches, including multilineage organoids, functionalized hydrogels, decellularized matrices and bioprinting, aim to recreate the native islet microenvironment, while synthetic biology approaches, such as hypoimmune gene editing, CRISPR-based transcriptional control and stimulus-responsive survival circuits, seek to enhance grafts' resilience. Computational and single-cell approaches, including gene regulatory network analysis and digital twin frameworks, are beginning to provide predictive tools for benchmarking differentiation quality and forecasting graft outcomes. Together, these complementary strategies, potentially tailored to individual patients, represent a realistic path towards safer, more effective and durable β-cell replacement therapies for type 1 diabetes.
PMID 43010164
Read full article →PubMedFrontiers in medicine2026-11-11
Hepatic steatosis is associated with postprandial dysglycemia in type 1 diabetes: insights from dual-modality liver assessment.
Li Shuang S, Wang Panzun P, Cai Zhihong Z, Gao Tianyu T et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in type 1 diabetes (T1D), yet its relationship with dynamic glycemic abnormalities and the metabolic pathways underlying these associations remains incompletely understood. We investigated the associations of hepatic steatosis with conventional and continuous glucose monitoring (CGM)-derived glycemic measures in T1D and explored the potential roles of circulating insulin-like growth factor-1 (IGF-1) and insulin resistance. This cross-sectional study included 231 individuals with T1D who underwent hepatic steatosis assessment using ultrasonography and controlled attenuation parameter (CAP). Glycemic status was characterized using glycated hemoglobin (HbA1c), fasting plasma glucose, 1,5-anhydroglucitol (1,5-AG), and, in 142 participants, at least 72 h of valid CGM under standardized inpatient conditions. Multivariable linear regression, false discovery rate correction, and exploratory serial mediation analyses were performed. Ultrasound-defined MASLD was present in 50 participants (21.6%). After multivariable adjustment, ultrasound-defined MASLD and greater CAP were consistently associated with lower 1,5-AG concentrations and less favorable CGM profiles, including higher 2-hour postprandial glucose, glucose peak, mean glucose, glucose management indicator, and time above range, together with lower time in range, whereas fasting glucose was not significantly associated with hepatic steatosis. Hepatic steatosis was also associated with lower circulating IGF-1 concentrations and greater insulin resistance across multiple surrogate indices. In exploratory serial mediation analysis using TG/HDL-C as the primary insulin resistance measure, the combined indirect association through IGF-1 and insulin resistance accounted for 82.6% of the association between MASLD and lower 1,5-AG concentrations, with consistent patterns observed using alternative insulin resistance indices. Hepatic steatosis in T1D is independently associated with a distinct dysglycemic phenotype characterized particularly by short-term and postprandial hyperglycemia. Concurrent differences in circulating IGF-1 and insulin sensitivity may statistically account for a substantial proportion of this association. These findings support hepatic steatosis as a clinically relevant metabolic comorbidity in T1D and warrant prospective studies to clarify the underlying temporal and biological relationships.
PMID 43011355
Read full article →PubMedInsect science2026-11-11
ROS-dependent phosphorylation of insulin receptor and insulin receptor substrate during pupal diapause development in the cotton bollworm, Helicoverpa armigera.
Su Zhiren Z, Yang Yongpan Y, Ke Yafang Y, Xu Wei-Hua WH et al.
Insect diapause is a critical adaptive strategy characterized by developmental arrest and enhanced stress tolerance, orchestrated by intricate molecular networks. The insulin signaling pathway, which governs growth, metabolism, and stress responses, has been implicated in diapause regulation. However, the precise roles of insulin receptor (InR) and insulin receptor substrate (IRS) in modulating pupal diapause remain incompletely understood, particularly in the economically important pest Helicoverpa armigera. Here, we show that InR and IRS are associated with pupal diapause development through redox-sensitive phosphorylation cascades. Temporal profiling revealed a marked upregulation of phosphorylated InR (p-InR) and IRS (p-IRS) in diapause-destined pupal brains, concomitant with elevated phosphorylation of Akt (p-Akt) and ERK (p-ERK). Functional validation in Helicoverpa zea (HzAm1) cells, via overexpression and RNA interference (RNAi), showed that IRS positively regulates Akt and ERK signaling. Further mechanistic studies indicated that reactive oxygen species (ROS) act upstream of the phosphorylation of InR, IRS, Akt, and ERK in vitro and in vivo; these effects were reversible upon ROS scavenging. Further investigations revealed that increased p-ERK was associated with global protein ubiquitination, suggesting this kinase as a key regulator of proteasomal degradation in diapause development. Our findings delineate a ROS-InR-IRS-Akt/ERK signaling framework associated with diapause development and proteostatic regulation in H. armigera, thereby advancing our understanding of insect diapause biology and providing candidate molecular targets for future pest-management interventions.
PMID 43012655
Read full article →+9996 more articles available with a free account
Sign up free to view all articles →